PEA-OXA restores cognitive impairments associated with vitamin D deficiency-dependent alterations of the gut microbiota

Francesca Guida, Monica Iannotta, Michela Perrone, Rosmara Infantino, Giada Giorgini, Antimo Fusco, Ida Marabese, Iolanda Manzo, Carmela Belardo, Emanuele Di Martino, Salvatore Pagano, Serena Boccella, Cristoforo Silvestri, Livio Luongo, Vincenzo Di Marzo, Sabatino Maione. Biomed Pharmacother. 2024 Jun:175:116600.

Laboratory studyOther animalsWith PEA-OXA (2-pentadecyl-2-oxazoline, a PEA analogue, tested alone)

This study tested palmitoylethanolamide together with PEA-OXA (2-pentadecyl-2-oxazoline, a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design

Laboratory study

Subjects

Mice made vitamin D deficient, male and female; numbers not stated in the abstract

Dose used in the study

Not stated in the abstract

Duration

Not stated in the abstract

What was measured

Cognitive behaviour, hippocampal long-term potentiation, hippocampal neuroinflammation, and gut microbiota composition.

What the authors reported

PEA-OXA countered the cognitive impairment and the biochemical and electrophysiological changes seen in vitamin D deficient mice, which otherwise showed poorer cognition, impaired long-term potentiation and hippocampal neuroinflammation. PEA-OXA also raised gut microbiota diversity (lowered by deficiency in female mice only), increased Aerococcaceae and Butyricicoccaceae, and reversed the loss of Blautia in females and Roseburia in males.

Limits of this study

A mouse model; it cannot show effect in people. The abstract gives no dose, route, group sizes or treatment length. PEA-OXA is an analogue, not palmitoylethanolamide itself. The authors declare no conflict of interest.

Source

PubMed 38670046 · doi:10.1016/j.biopha.2024.116600

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.